Investors

IR Overview

News

Date Title  
Toggle Summary Adaptimmune Announces Opening of Phase I/IIa Clinical Trial in Ovarian Cancer
Adaptimmune announced today that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer at Roswell Park Cancer Institute (RPCI) in Buffalo, N.Y., and City of Hope (COH) in Duarte, Calif. Researchers will investigate the safety, bioactivity and
Adaptimmune Announces Opening of Phase I/IIa Clinical Trial in Ovarian Cancer
Adaptimmune announced today that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer at Roswell Park Cancer Institute (RPCI) in Buffalo, N.Y., and City of Hope (COH) in Duarte, Calif. Researchers will investigate the safety, bioactivity and
Toggle Summary Adaptimmune enters into Cell Therapy Manufacturing Services Agreement with NeoStem Subsidiary, Progenitor Cell Therapy
NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy LLC (“PCT”), together with Adaptimmune Limited and Adaptimmune LLC (collectively, “Adaptimmune”), announced today a Services Agreement under which PCT will provide services to support Adaptimmune’s NYESO-1c259-T cell therapy
Adaptimmune enters into Cell Therapy Manufacturing Services Agreement with NeoStem Subsidiary, Progenitor Cell Therapy
NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy LLC (“PCT”), together with Adaptimmune Limited and Adaptimmune LLC (collectively, “Adaptimmune”), announced today a Services Agreement under which PCT will provide services to support Adaptimmune’s NYESO-1c259-T cell therapy
Toggle Summary Preliminary Results from an Early Phase Trial of Gene Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma
(Atlanta, GA and Oxford, UK) 10 December, 2012.  Adaptimmune today announces the release of preliminary results from an early phase clinical study using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells.  Lead investigators for the study
Preliminary Results from an Early Phase Trial of Gene Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma
(Atlanta, GA and Oxford, UK) 10 December, 2012.  Adaptimmune today announces the release of preliminary results from an early phase clinical study using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells.  Lead investigators for the study
Toggle Summary Investigators to Present Preliminary Adaptimmune’s Findings for Gene Engineered T Cells in Myeloma
Adaptimmune announces the publication of dual abstracts in today’s issue of the Journal Blood, which report preliminary results from an early phase study using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells.  Lead investigators for the study will
Investigators to Present Preliminary Adaptimmune’s Findings for Gene Engineered T Cells in Myeloma
Adaptimmune announces the publication of dual abstracts in today’s issue of the Journal Blood, which report preliminary results from an early phase study using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells.  Lead investigators for the study will
Toggle Summary Adaptimmune is strengthening its Board
Adaptimmune announces New Board Appointments as clinical programmes get underway. Please click here for full Press Release
Adaptimmune is strengthening its Board
Adaptimmune announces New Board Appointments as clinical programmes get underway. Please click here for full Press Release
Toggle Summary Opening of Pilot Clinical Trial in Synovial Sarcoma
Adaptimmune announced today that it has opened a Pilot, open‐label clinical trial in synovial sarcoma at the National Cancer Institute (NCI), Bethesda, Maryland. Please click here for Press Release  
Opening of Pilot Clinical Trial in Synovial Sarcoma
Adaptimmune announced today that it has opened a Pilot, open‐label clinical trial in synovial sarcoma at the National Cancer Institute (NCI), Bethesda, Maryland. Please click here for Press Release  
Toggle Summary Opening of Phase I/II Clinical Trial for Metastatic Melanoma
Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri.   Please click here for Press Release
Opening of Phase I/II Clinical Trial for Metastatic Melanoma
Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri.   Please click here for Press Release
Toggle Summary Opening of Phase I/II Clinical Trial in Multiple Myeloma
Adaptimmune has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy. Please click here for Press Release
Opening of Phase I/II Clinical Trial in Multiple Myeloma
Adaptimmune has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy. Please click here for Press Release
Toggle Summary Adaptimmune announces launch of US Subsidiary
Adaptimmune Limited today announced that it has launched a US subsidiary, Adaptimmune LLC, located in Philadelphia, and appointed Dr Gwen Binder-Scholl as Vice President of Operations of the new company. Please click on this link to download the full Press Release
Adaptimmune announces launch of US Subsidiary
Adaptimmune Limited today announced that it has launched a US subsidiary, Adaptimmune LLC, located in Philadelphia, and appointed Dr Gwen Binder-Scholl as Vice President of Operations of the new company. Please click on this link to download the full Press Release
Toggle Summary Adaptimmune announces first ever clinical trial with engineered T cells designed to clear HIV infection
Oxford, UK and Philadelphia, PA: 7 October 2009. Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine announce the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever
Adaptimmune announces first ever clinical trial with engineered T cells designed to clear HIV infection
Oxford, UK and Philadelphia, PA: 7 October 2009. Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine announce the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever
Toggle Summary Press Release: Adaptimmune engineers immune cells able to clear HIV – clinical trials planned
Click below to download Press Release :- Adaptimmune Ltd Press Release – 09 Nov 2008
Press Release: Adaptimmune engineers immune cells able to clear HIV – clinical trials planned
Click below to download Press Release :- Adaptimmune Ltd Press Release – 09 Nov 2008
Toggle Summary Adaptimmune officially founded
Adaptimmune was officially founded on the 1st July 2008 with the remit of advancing the use of engineered T cell receptors in adoptive T cell therapy.
Adaptimmune officially founded
Adaptimmune was officially founded on the 1st July 2008 with the remit of advancing the use of engineered T cell receptors in adoptive T cell therapy.